Bugs & Drugs Primer Needs Assessment

Dear Infectious Diseases Training Program Director and Fellows:

We are in the process of updating and enhancing the IDSA Core Antimicrobial Stewardship Curriculum. One enhancement will be the addition of a stewardship-focused microbiology and pharmacology (Bugs & Drugs) primer for ID fellows. Your input will be extremely valuable as we are developing content for this primer. Please take a few minutes to answer the following questions to help us best understand the needs of training programs in these areas. We anticipate this survey will take approximately 5 minutes to complete.

Thank you!

IDSA Antimicrobial Stewardship Curriculum Workgroup

Select current role: *

Program Director

ID Fellow

Other

Select current role: Other

Fellowship Year

1

2

3

With regard to clinical microbiology, how satisfied are you with your 1st year fellows’ current training?

With regard to clinical pharmacology, how satisfied are you with your 1st year fellows’ current training?

How useful would a primer on microbiology and pharmacology be to your fellowship training program?

How likely would you be to incorporate educational materials from an IDSA sponsored microbiology and pharmacology primer into your fellowship training program?

Considering the numerous educational priorities and demands on fellow time, If you were to incorporate educational materials from an IDSA sponsored microbiology and pharmacology primer into your fellowship training program, how many hours of curricular time would you likely be able to devote to the primer?

Considering the numerous educational priorities and demands on fellow time, If you were to incorporate educational materials from an IDSA sponsored microbiology and pharmacology primer into your fellowship training program, how many hours of curricular time would you likely be able to devote to the primer? Other

Does your institution have an onsite microbiology laboratory?

Yes

No

Do your fellows rotate through the microbiology laboratory in some capacity during their training?

Yes

No

In which of the following activities do your fellows participate?

Micro lab rounds

Micro rotation

Other

In which of the following activities do your fellows participate? Other

Do your fellows have the opportunity to rotate in a nearby laboratory?

Yes

No

Other

Do your fellows have the opportunity to rotate in a nearby laboratory? Other

Are the following topics currently included in your ID fellowship training program curriculum?

	Yes	No
Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test)	Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test) - Yes	Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test) - No
Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR)	Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR) - Yes	Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR) - No
Clinical use and limitations of rapid diagnostic techniques	Clinical use and limitations of rapid diagnostic techniques - Yes	Clinical use and limitations of rapid diagnostic techniques - No
Commonly used methods of antimicrobial susceptibility testing	Commonly used methods of antimicrobial susceptibility testing - Yes	Commonly used methods of antimicrobial susceptibility testing - No
Principles of MIC interpretation	Principles of MIC interpretation - Yes	Principles of MIC interpretation - No
Clinical application of CLSI data	Clinical application of CLSI data - Yes	Clinical application of CLSI data - No

When considering your fellowship program’s current curricula and potential areas for enhancement, how important would each of the following topics be to include in a Bugs & Drugs primer?

(0=not important, 1=slightly important, 2=moderately important, 3=very important, 4=extremely important).

	0	1	2	3	4
Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test)	Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test) - 0	Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test) - 1	Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test) - 2	Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test) - 3	Culture-based rapid diagnostic techniques (e.g. gram stain, catalase test) - 4
Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR)	Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR) - 0	Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR) - 1	Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR) - 2	Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR) - 3	Non-culture-based rapid diagnostic techniques (e.g. multiplex PCR) - 4
Clinical use and limitations of rapid diagnostic techniques	Clinical use and limitations of rapid diagnostic techniques - 0	Clinical use and limitations of rapid diagnostic techniques - 1	Clinical use and limitations of rapid diagnostic techniques - 2	Clinical use and limitations of rapid diagnostic techniques - 3	Clinical use and limitations of rapid diagnostic techniques - 4
Commonly used methods of antimicrobial susceptibility testing	Commonly used methods of antimicrobial susceptibility testing - 0	Commonly used methods of antimicrobial susceptibility testing - 1	Commonly used methods of antimicrobial susceptibility testing - 2	Commonly used methods of antimicrobial susceptibility testing - 3	Commonly used methods of antimicrobial susceptibility testing - 4
Principles of MIC interpretation	Principles of MIC interpretation - 0	Principles of MIC interpretation - 1	Principles of MIC interpretation - 2	Principles of MIC interpretation - 3	Principles of MIC interpretation - 4
Clinical application of CLSI data	Clinical application of CLSI data - 0	Clinical application of CLSI data - 1	Clinical application of CLSI data - 2	Clinical application of CLSI data - 3	Clinical application of CLSI data - 4

Are the following topics currently included in your ID fellowship training program curriculum?

	Yes	No
Staphylococcus aureus	Staphylococcus aureus - Yes	Staphylococcus aureus - No
Coagulase negative Staphylococcus spp. (non-lugdunensis spp.)	Coagulase negative Staphylococcus spp. (non-lugdunensis spp.) - Yes	Coagulase negative Staphylococcus spp. (non-lugdunensis spp.) - No
Staphylococcus lugdunensis	Staphylococcus lugdunensis - Yes	Staphylococcus lugdunensis - No
Enterococcus spp.	Enterococcus spp. - Yes	Enterococcus spp. - No
Streptococcus pyogenes	Streptococcus pyogenes - Yes	Streptococcus pyogenes - No
Streptococcus pneumoniae	Streptococcus pneumoniae - Yes	Streptococcus pneumoniae - No
Enterobacterales	Enterobacterales - Yes	Enterobacterales - No
Clostridioides difficile	Clostridioides difficile - Yes	Clostridioides difficile - No
Pseudomonas spp.	Pseudomonas spp. - Yes	Pseudomonas spp. - No
Acinetobacter spp.	Acinetobacter spp. - Yes	Acinetobacter spp. - No
Candida spp.	Candida spp. - Yes	Candida spp. - No

How important is each one of the following pathogens to include in a Bugs & Drugs primer?

(0=not important, 1=slightly important, 2=moderately important, 3=very important, 4=extremely important).

	0	1	2	3	4
Staphylococcus aureus	Staphylococcus aureus - 0	Staphylococcus aureus - 1	Staphylococcus aureus - 2	Staphylococcus aureus - 3	Staphylococcus aureus - 4
Coagulase negative Staphylococcus spp. (non-lugdunensis spp.)	Coagulase negative Staphylococcus spp. (non-lugdunensis spp.) - 0	Coagulase negative Staphylococcus spp. (non-lugdunensis spp.) - 1	Coagulase negative Staphylococcus spp. (non-lugdunensis spp.) - 2	Coagulase negative Staphylococcus spp. (non-lugdunensis spp.) - 3	Coagulase negative Staphylococcus spp. (non-lugdunensis spp.) - 4
Staphylococcus lugdunensis	Staphylococcus lugdunensis - 0	Staphylococcus lugdunensis - 1	Staphylococcus lugdunensis - 2	Staphylococcus lugdunensis - 3	Staphylococcus lugdunensis - 4
Enterococcus spp.	Enterococcus spp. - 0	Enterococcus spp. - 1	Enterococcus spp. - 2	Enterococcus spp. - 3	Enterococcus spp. - 4
Streptococcus pyogenes	Streptococcus pyogenes - 0	Streptococcus pyogenes - 1	Streptococcus pyogenes - 2	Streptococcus pyogenes - 3	Streptococcus pyogenes - 4
Streptococcus pneumoniae	Streptococcus pneumoniae - 0	Streptococcus pneumoniae - 1	Streptococcus pneumoniae - 2	Streptococcus pneumoniae - 3	Streptococcus pneumoniae - 4
Enterobacterales	Enterobacterales - 0	Enterobacterales - 1	Enterobacterales - 2	Enterobacterales - 3	Enterobacterales - 4
Clostridioides difficile	Clostridioides difficile - 0	Clostridioides difficile - 1	Clostridioides difficile - 2	Clostridioides difficile - 3	Clostridioides difficile - 4
Pseudomonas spp.	Pseudomonas spp. - 0	Pseudomonas spp. - 1	Pseudomonas spp. - 2	Pseudomonas spp. - 3	Pseudomonas spp. - 4
Acinetobacter spp.	Acinetobacter spp. - 0	Acinetobacter spp. - 1	Acinetobacter spp. - 2	Acinetobacter spp. - 3	Acinetobacter spp. - 4
Candida spp.	Candida spp. - 0	Candida spp. - 1	Candida spp. - 2	Candida spp. - 3	Candida spp. - 4

Are the following topics currently included in your ID fellowship training program curriculum?

	Yes	No
Antibiotic safety (adverse effects, drug-drug interactions)	Antibiotic safety (adverse effects, drug-drug interactions) - Yes	Antibiotic safety (adverse effects, drug-drug interactions) - No
Antibiotic resistance mechanisms	Antibiotic resistance mechanisms - Yes	Antibiotic resistance mechanisms - No
Novel antibiotic agents	Novel antibiotic agents - Yes	Novel antibiotic agents - No
General pharmacokinetics (absorption, distribution, metabolism, etc.)	General pharmacokinetics (absorption, distribution, metabolism, etc.) - Yes	General pharmacokinetics (absorption, distribution, metabolism, etc.) - No
Pharmacokinetics in special populations (critical illness, obesity, etc.)	Pharmacokinetics in special populations (critical illness, obesity, etc.) - Yes	Pharmacokinetics in special populations (critical illness, obesity, etc.) - No
Clinical applications of pharmacodynamics (AUC/MIC, etc.)	Clinical applications of pharmacodynamics (AUC/MIC, etc.) - Yes	Clinical applications of pharmacodynamics (AUC/MIC, etc.) - No
Therapeutic drug monitoring (peaks, troughs, AUC)	Therapeutic drug monitoring (peaks, troughs, AUC) - Yes	Therapeutic drug monitoring (peaks, troughs, AUC) - No

When considering your fellowship program’s current curricula and potential areas for enhancement, how important would each of the following topics be to include in a Bugs & Drugs primer?

(0=not important, 1=slightly important, 2=moderately important, 3=very important, 4=extremely important).

	0	1	2	3	4
Antibiotic safety (adverse effects, drug-drug interactions)	Antibiotic safety (adverse effects, drug-drug interactions) - 0	Antibiotic safety (adverse effects, drug-drug interactions) - 1	Antibiotic safety (adverse effects, drug-drug interactions) - 2	Antibiotic safety (adverse effects, drug-drug interactions) - 3	Antibiotic safety (adverse effects, drug-drug interactions) - 4
Antibiotic resistance mechanisms	Antibiotic resistance mechanisms - 0	Antibiotic resistance mechanisms - 1	Antibiotic resistance mechanisms - 2	Antibiotic resistance mechanisms - 3	Antibiotic resistance mechanisms - 4
Novel antibiotic agents	Novel antibiotic agents - 0	Novel antibiotic agents - 1	Novel antibiotic agents - 2	Novel antibiotic agents - 3	Novel antibiotic agents - 4
General pharmacokinetics (absorption, distribution, metabolism, etc.)	General pharmacokinetics (absorption, distribution, metabolism, etc.) - 0	General pharmacokinetics (absorption, distribution, metabolism, etc.) - 1	General pharmacokinetics (absorption, distribution, metabolism, etc.) - 2	General pharmacokinetics (absorption, distribution, metabolism, etc.) - 3	General pharmacokinetics (absorption, distribution, metabolism, etc.) - 4
Pharmacokinetics in special populations (critical illness, obesity, etc.)	Pharmacokinetics in special populations (critical illness, obesity, etc.) - 0	Pharmacokinetics in special populations (critical illness, obesity, etc.) - 1	Pharmacokinetics in special populations (critical illness, obesity, etc.) - 2	Pharmacokinetics in special populations (critical illness, obesity, etc.) - 3	Pharmacokinetics in special populations (critical illness, obesity, etc.) - 4
Clinical applications of pharmacodynamics (AUC/MIC, etc.)	Clinical applications of pharmacodynamics (AUC/MIC, etc.) - 0	Clinical applications of pharmacodynamics (AUC/MIC, etc.) - 1	Clinical applications of pharmacodynamics (AUC/MIC, etc.) - 2	Clinical applications of pharmacodynamics (AUC/MIC, etc.) - 3	Clinical applications of pharmacodynamics (AUC/MIC, etc.) - 4
Therapeutic drug monitoring (peaks, troughs, AUC)	Therapeutic drug monitoring (peaks, troughs, AUC) - 0	Therapeutic drug monitoring (peaks, troughs, AUC) - 1	Therapeutic drug monitoring (peaks, troughs, AUC) - 2	Therapeutic drug monitoring (peaks, troughs, AUC) - 3	Therapeutic drug monitoring (peaks, troughs, AUC) - 4

Please list any additional Microbiology or Pharmacology topics that you would want to have included in this primer for the antimicrobial steward:

what microbiology or pharmacology-related training techniques have you currently been using that you have found beneficial?

what changes (if any) related to microbiology or pharmacology training has your program made in response to the COVID-19 pandemic?

Please provide your e-mail address:

optional

You are here

Bugs & Drugs Primer Needs Assessment